A Physiologically‐Based Pharmacokinetic Model for the Prediction of “Half‐Life Extension” and “Catch and Release” Monoclonal Antibody Pharmacokinetics
Copyright policy )A Physiologically‐Based Pharmacokinetic Model for the Prediction of “Half‐Life Extension” and “Catch and Release” Monoclonal Antibody Pharmacokinetics
Monoclonal antibodies (mAbs) can be engineered to have “extended half‐life” and “catch and release” properties to improve target coverage. We have developed a mAb physiologically‐based pharmacokinetic model that describes intracellular trafficking, neonatal Fc receptor (FcRn) recycling, and nonspecific clearance of mAbs. We extended this model to capture target binding as a function of target affinity, expression, and turnover. For mAbs engineered to have an extended half‐life, the model was able to accurately predict the terminal half‐life (82% within 2‐fold error of the observed value) in the human FcRn transgenic (Tg32) homozygous mouse and human. The model also accurately captures the trend in pharmacokinetic and target coverage data for a set of mAbs with differing catch and release properties in the Tg32 mouse. The mechanistic nature of this model allows us to explore different engineering techniques early in drug discovery, potentially expanding the number of “druggable” targets.
- RES Group, Inc. United States
- Pfizer (United States) United States
Mice, Transgenic, RM1-950, Receptors, Fc, HIV Antibodies, Antibodies, Monoclonal, Humanized, Protein Engineering, Mice, Drug Development, Drug Discovery, Animals, Humans, Computer Simulation, Research, Histocompatibility Antigens Class I, Homozygote, Models, Immunological, Antibodies, Monoclonal, Mutation, Therapeutics. Pharmacology, Broadly Neutralizing Antibodies, Half-Life, Protein Binding
Mice, Transgenic, RM1-950, Receptors, Fc, HIV Antibodies, Antibodies, Monoclonal, Humanized, Protein Engineering, Mice, Drug Development, Drug Discovery, Animals, Humans, Computer Simulation, Research, Histocompatibility Antigens Class I, Homozygote, Models, Immunological, Antibodies, Monoclonal, Mutation, Therapeutics. Pharmacology, Broadly Neutralizing Antibodies, Half-Life, Protein Binding
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).14 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!